Abstract
Fibroproliferative disorders such as systemic sclerosis (SSc) have no effective therapies and result in significant morbidity and mortality. We recently demonstrated that the C-terminal domain of endostatin, known as E4, prevented and reversed both dermal and pulmonary fibrosis. Our goal was to identify the mechanism by which E4 abrogates fibrosis and its cell surface binding partner(s). Our findings show that E4 activated the urokinase pathway and increased the urokinase plasminogen activator (uPA) to type 1 plasminogen activator inhibitor (PAI-1) ratio. In addition, E4 substantially increased MMP-1 and MMP-3 expression and activity. In vivo, E4 reversed bleomycin induction of PAI-1 and increased uPA activity. In patients with SSc, the uPA/PAI-1 ratio was decreased in both lung tissues and pulmonary fibroblasts compared with normal donors. Proteins bound to biotinylated-E4 were identified as enolase-1 (ENO) and uPA receptor (uPAR). The antifibrotic effects of E4 required uPAR. Further, ENO mediated the fibrotic effects of TGF-β1 and exerted TGF-β1–independent fibrotic effects. Our findings suggest that the antifibrotic effect of E4 is mediated, in part, by regulation of the urokinase pathway and induction of MMP-1 and MMP-3 levels and activity in a uPAR-dependent manner, thus promoting extracellular matrix degradation. Further, our findings identify a moonlighting function for the glycolytic enzyme ENO in fibrosis.
Highlights
Fibrosis is characterized by fibroblast activation and excess deposition of extracellular matrix (ECM) proteins, such as fibronectin and collagen, in an organ or tissue
Our data show that ENO bound uPA receptor (uPAR) at baseline, but the relative binding of these molecules was reduced by TGF-β1; the interaction was restored in the presence of E4 (Figure 1D)
We show that E4 exerts its antifibrotic effects via activation of urokinase and the plasminogen pathway, including activation of MMP-1 and MMP-3, promoting ECM degradation
Summary
Fibrosis is characterized by fibroblast activation and excess deposition of extracellular matrix (ECM) proteins, such as fibronectin and collagen, in an organ or tissue. Fibrosis results in loss of organ function and is the major cause of morbidity and mortality in progressive fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc) [1]. Pulmonary involvement is the leading cause of morbidity and mortality in patients with SSc [3]. The drugs pirfenidone and nintedanib were approved by the FDA for the treatment of IPF, and the latter was approved for the treatment of SSc [4,5,6]. These drugs reduce the rate of disease progression, neither drug halts or reverses lung fibrosis. The need for the development of an effective therapy for lung fibrosis is undiminished
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
